At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
In Brief
A Phase 4 clinical trial evaluating Patiromer 25.2 g for Kidney Failure, Chronic. Completed, enrolled 43 participants across 1 site.
Detailed Summary
The Investigator hypothesize that a single dose of patiromer will lower serum potassium levels in less than 6hrs. Since a dosage of 30g/day for a period of 4 weeks has been studied in at least two multicenter randomized controlled trials, the Investigator further hypothesize that a single dose of 25.2g of patiromer will be well tolerated in hyperkalemic patients in the Emergency Department setting. The FDA approved dosage of 25.2g is appropriate for this study because the research staff will enroll patients with moderate (K greater than 6 mEq/L) to severe hyperkalemia, and the higher dosage has typically been used in this population for more effective control.
Study Details
Timeline
Interventions
Single dose of Patiromer 25.2 g